Narcan Nasal Spray for OTC use is expected to be available by late summer and will have the same formulation, device design, and 4mg strength as the prescription product.
News and Features
Incidence rate of peripheral artery disease similar for current users of smokeless tobacco, cigarette smokers.
Four major drug types were examined: psychostimulants with addiction potential, heroin, natural and semisynthetic opioids, and synthetic opioids.
Highest odds of opioid overdose seen when both the individual and another household member had opioid fills in previous 6 months.
The product was designed using the Amphastar’s proprietary nasal delivery device.
Opioids accounted for 24.1 percent of substances contributing to deaths in 2005 and 52.2 percent in 2018
In 2011, following reports of serious livery injury, the FDA had required manufacturers of prescription acetaminophen combination products to limit the amount of acetaminophen to 325mg per tablet or capsule.
While not approved for human use, xylazine has been detected in combination with opioids (eg, illicit fentanyl), and with stimulants (eg, methamphetamine, cocaine).
Agency has faced criticism from antitobacco advocates, the industry, and lawmakers for its past work in cigarette and vaping regulation
Proportion of deaths co-involving methamphetamine and heroin or fentanyl peaked at 61.2 percent in 2021
Adverse outcomes included small for gestational age, medically indicated preterm birth, stillbirth, or hypertensive disorders of pregnancy
Narcan Nasal Spray is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
Authors say this may reflect peer influence on substance use, as decreases were not seen for older adults
Authors say providers should routinely ask older adults about cannabis use
Under the FDA’s orders, the Company may not market or distribute these products in the US.
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
OPNT003 is an intranasal formulation containing the high affinity opioid antagonist, nalmefene.
Canadian provinces permitting edible cannabis sales experienced much larger increases in hospitalizations for unintentional poisoning
Maternal, neonatal outcomes similar to buprenorphine monotherapy